From label scan
No label facts are available for this entry yet.
What we know
Label-derived facts remain separate from AI-generated context.
AI context
No AI context is available yet.
Research and sources
Community-supplied references. Check the linked source before relying on a claim.
Label and use
Practical details pulled from scanned or cited interventions.
What it is for
- **Glycemic control in type 2 diabetes** (approved use).
- **Delay / prevention of type 2 diabetes in high-risk prediabetes** (DPP claim; not an aging claim).
- **Reduction of diabetes-related complications, myocardial infarction, and death in overweight new-onset T2D** (UKPDS 34 claim).
- **Human lifespan extension / delayed aging** (longevity claim; TAME).
- **Human healthspan / delayed multimorbidity of aging in people without diabetes** (longevity claim).
- **Cardiovascular protection outside the UKPDS overweight-T2D setting** (observational + extrapolated claim).
- **Cancer prevention or adjuvant cancer benefit** (observational + oncology claim).
- **Weight loss** (secondary / community claim).
- **Improved physical function, sarcopenia, or frailty** (geroscience claim).
- **Better exercise adaptations or “exercise in a pill”** (community claim; the evidence runs the other way).
Observed use
Dose, timing, and brands from 2 public protocols. Private and hidden usage is excluded.
Dosage
- 500 mg1× · 50%
- 800-1,000 mg1× · 50%
Timing
- 6-week cycles on/off1× · 50%
- Evening1× · 50%
Protocols
Where this intervention appears and what it tends to sit beside.